Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)
Funding Amount
Up to $400,000
Deadline
November 5, 2028
718 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public colleges & universities
- School districts
- Small businesses
- Nonprofits (501(c)(3))
- For-profit businesses
- Special district governments
- County governments
- Tribal governments
Other requirements
- Territory or Possession.
Overview
The purpose of this Notice of Funding Opportunity (NOFO) is tofurther elucidate the mechanisms of early immune development in utero, during the early post-natal period and during early childhood in neonates, infants, and children and adolescents with or without in-utero exposure to HIV or Anti-Retroviral Therapeutics (ART).This initiative aims to understand intricate mechanisms of immune cells at the maternal-fetal interface, T and B cell development and maturation in offspring, and local immune responses and the role of systemic immunity.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: PAR-25-362
- Instrument: grant
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Focus Areas & Funding Uses
Fields of Work
- Science research
- Healthcare
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $375,000
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,400,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Technology Projects (SenTecs) (UG3/UH3 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,000,000 total
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,500,000 total
Deadline
November 23, 2026
Ready to apply for Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Early Immune System Development and Ontogeny (R01 Clinical Trial Optional). Now let's win it.